Zacks Research Brokers Raise Earnings Estimates for Azitra

Azitra, Inc. (NYSEAMERICAN:AZTR – Free Report) – Analysts at Zacks Research lifted their Q3 2026 earnings per share estimates for shares of Azitra in a note issued to investors on Monday, September 28th. Zacks Research analyst J. Vandermosten now forecasts that the company will post earnings of ($0.02) per share for the quarter, up from their previous estimate of ($0.04). The consensus estimate for Azitra’s current full-year earnings is ($0.20) per share. Zacks Research also issued estimates for Azitra’s Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.06) EPS and FY2028 earnings at ($0.06) EPS.

Get Azitra alerts:

Azitra (NYSEAMERICAN:AZTR – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.05).

Azitra Stock Down 6.6%

NYSEAMERICAN AZTR opened at $0.13 on Thursday. Azitra has a 1-year low of $0.10 and a 1-year high of $1.09. The business’s 50-day simple moving average is $0.15 and its 200-day simple moving average is $0.19.

About Azitra

(Get Free Report)

Azitra, Inc is a clinical-stage biotechnology company focused on developing precision dermatology treatments for inflammatory and other skin conditions. The company uses engineered microbes and its proprietary platform to discover and develop live biotherapeutic products intended to address disease-related changes in the skin microbiome and deliver therapeutic proteins locally.

Azitra’s product pipeline has included ATR-12, an engineered strain of Staphylococcus epidermidis designed to produce filaggrin-1 for the potential treatment of Netherton syndrome, a rare genetic skin disorder.

Recommended Stories

• Five stocks we like better than Azitra
• Everyone in AI Is Quietly Copying Palantir’s Playbook
• Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
• JPMorgan Bets on Genius Sports as the Market Loses Patience
• Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question

Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.